Will West
Nessuna posizione attualmente
Storia della carriera di Will West
Precedenti posizioni note di Will West
Società | Posizione | Inizio | Fine |
---|---|---|---|
Odontis Ltd.
Odontis Ltd. Miscellaneous Commercial ServicesCommercial Services Odontis is developing a biological replacement tooth product - the BioToothTM. The research is lead by Professor Paul Sharpe at King's College London Dental Institute. His team has demonstrated that tooth development can be initiated in stem cells, and that fully formed teeth can be created in developmental models. This is pioneering in that it represents one of the very few examples of a fully integrated tissue engineered organ. The technology opens the potential for the implantation of cultured cells in patients to grow and replace damaged or missing teeth. Odontis has attracted over £2 million of funding to date to progress the technology to commercial development. | Corporate Officer/Principal | 20/11/2009 | 18/01/2011 |
Procter & Gamble Health & Beauty Care | Corporate Officer/Principal | - | - |
Formazione di Will West
London Business School | Masters Business Admin |
Statistiche
Distribuzione geografica
Regno Unito | 3 |
Stati Uniti | 2 |
Posizioni
Corporate Officer/Principal | 2 |
Masters Business Admin | 1 |
Settori
Commercial Services | 2 |
Miscellaneous | 2 |
Consumer Services | 2 |
Posizioni ricoperte
Attive
Inattive
Società quotate in Borsa
Aziende private
Società collegate
Aziende private | 2 |
---|---|
Odontis Ltd.
Odontis Ltd. Miscellaneous Commercial ServicesCommercial Services Odontis is developing a biological replacement tooth product - the BioToothTM. The research is lead by Professor Paul Sharpe at King's College London Dental Institute. His team has demonstrated that tooth development can be initiated in stem cells, and that fully formed teeth can be created in developmental models. This is pioneering in that it represents one of the very few examples of a fully integrated tissue engineered organ. The technology opens the potential for the implantation of cultured cells in patients to grow and replace damaged or missing teeth. Odontis has attracted over £2 million of funding to date to progress the technology to commercial development. | Commercial Services |
Procter & Gamble Health & Beauty Care | Miscellaneous |
- Borsa valori
- Insiders
- Will West
- Esperienza